A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, 2-way Crossover Study Comparing AVP-786-20.5/4.75 (Deuterated [d6] Dextromethorphan Hydrobromide 20.5 mg/Quinidine Sulfate 4.75 mg) With AVP-923-20 (Dextromethorphan Hydrobromide 20 mg/ Quinidine Sulfate 10 mg).

Trial Profile

A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, 2-way Crossover Study Comparing AVP-786-20.5/4.75 (Deuterated [d6] Dextromethorphan Hydrobromide 20.5 mg/Quinidine Sulfate 4.75 mg) With AVP-923-20 (Dextromethorphan Hydrobromide 20 mg/ Quinidine Sulfate 10 mg).

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jul 2015

At a glance

  • Drugs Deudextromethorphan (Primary) ; Dextromethorphan/quinidine
  • Indications Major depressive disorder; Neurological disorders; Neuropathic pain; Psychiatric disorders
  • Focus Pharmacokinetics
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jan 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top